Organon Drug Patent Portfolio
Organon owns 26 orange book drugs protected by 111 US patents with Follistim having the least patent protection, holding only 1 patent. And Asmanex Twisthaler with maximum patent protection, holding 21 patents. Given below is the list of Organon's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11497718 | Use of tapinarof for the treatment of atopic dermatitis | 13 Nov, 2039 | Active |
| US11590088 | Use of Tapinarof for the treatment of chronic plaque psoriasis | 13 Nov, 2039 | Active |
| US11938099 | Use of tapinarof for the treatment of atopic dermatitis | 13 Nov, 2039 | Active |
| US10647649 | Process for preparing tapinarof | 13 Nov, 2038 | Active |
| US11597692 | Process for preparing tapinarof | 13 Nov, 2038 | Active |
| US11129896 | Topical formulations and treatments | 22 Sep, 2036 | Active |
| US12303563 | Topical formulations and treatments | 22 Sep, 2036 | Active |
| US10195160 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US10426743 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US11458108 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US11612573 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US11617724 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US11622945 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US9757552 | Applicator for inserting an implant | 28 Jul, 2030 | Active |
| US8722037 | X-ray visible drug delivery device | 28 Sep, 2027 | Active |
| US10821277 | Kit for and method of assembling an applicator for inserting an implant | 31 May, 2027 | Active |
| US8888745 | Applicator for inserting an implant | 28 Aug, 2026 | Active |
| US7612058 | Methods for inhibiting sterol absorption | 30 Apr, 2026 | Active |
| US7612058 | Methods for inhibiting sterol absorption | 30 Oct, 2025 | Expired |
| US8007830 | Granule formation | 24 Oct, 2022 | Expired |
| US7820199 | Stable extended release oral dosage composition | 28 Sep, 2022 | Expired |
| US7030106 | Sterol absorption inhibitor compositions | 25 Jul, 2022 | Expired |
| US6979463 | Stable extended release oral dosage composition | 28 Mar, 2022 | Expired |
| US7820199 | Stable extended release oral dosage composition | 28 Mar, 2022 | Expired |
| US7030106 | Sterol absorption inhibitor compositions | 25 Jan, 2022 | Expired |
| US7618649 | Extended release oral dosage composition | 19 Jun, 2021 | Expired |
| US6709676 | Extended release oral dosage composition | 18 Feb, 2021 | Expired |
| US7618649 | Extended release oral dosage composition | 19 Dec, 2020 | Expired |
| US8187630 | Extended release oral dosage composition | 19 Dec, 2020 | Expired |
| US7067502 | Combinations of formoterol and mometasone furoate for asthma | 21 Nov, 2020 | Expired |
| US7566705 | Combination of formoterol and mometasone furoate for asthma | 21 Nov, 2020 | Expired |
| US7067502 | Combinations of formoterol and mometasone furoate for asthma | 21 May, 2020 | Expired |
| US7566705 | Combination of formoterol and mometasone furoate for asthma | 08 May, 2020 | Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions | 07 Jan, 2020 | Expired |
| US7405223 | Treating allergic and inflammatory conditions | 07 Jan, 2020 | Expired |
| US7446090 | FSH formulation | 23 Aug, 2019 | Expired |
| US7563763 | FSH and FSH variant formulations, products and methods | 23 Aug, 2019 | Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions | 07 Jul, 2019 | Expired |
| US7405223 | Treating allergic and inflammatory conditions | 07 Jul, 2019 | Expired |
| US5994329 | Method for inhibiting bone resorption | 17 Jan, 2019 | Expired |
| US5942519 | Prevention of precipitated acute urinary retention | 23 Oct, 2018 | Expired |
| US6503537 | Preparation of powder agglomerates | 17 Sep, 2018 | Expired |
| US8173172 | Preparation of powder agglomerates | 17 Sep, 2018 | Expired |
| US5994329 | Method for inhibiting bone resorption | 17 Jul, 2018 | Expired |
| US6653286 | Gonadotropin releasing hormone antagonist | 16 Jun, 2018 | Expired |
| US5989581 | Drug delivery system for two or more active substances | 08 Apr, 2018 | Expired |
| US6127353 | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions | 03 Apr, 2018 | Expired |
| US6503537 | Preparation of powder agglomerates | 17 Mar, 2018 | Expired |
| US8173172 | Preparation of powder agglomerates | 17 Mar, 2018 | Expired |
| US5929028 | Liquid gonadotropin containing formulations | 14 Jan, 2018 | Expired |
| US6127353 | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions | 03 Oct, 2017 | Expired |
| US6068832 | Chlorofluorocarbon-free mometasone furoate aerosol formulations | 27 Aug, 2017 | Expired |
| US6240918 | Powdered medication inhaler | 20 Aug, 2017 | Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | 25 Apr, 2017 | Expired |
| USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | 25 Apr, 2017 | Expired |
| US6240918 | Powdered medication inhaler | 20 Feb, 2017 | Expired |
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) | 08 Jan, 2017 | Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | 25 Oct, 2016 | Expired |
| USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | 25 Oct, 2016 | Expired |
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) | 08 Jul, 2016 | Expired |
| US5829434 | Inhaler for powdered medications | 03 May, 2016 | Expired |
| US5607697 | Taste masking microparticles for oral dosage forms | 07 Dec, 2015 | Expired |
| US5829434 | Inhaler for powdered medications | 03 Nov, 2015 | Expired |
| US7211582 | Methods for treating urticaria using descarboethoxyloratadine | 30 Jun, 2015 | Expired |
| US7214683 | Compositions of descarboethoxyloratadine | 30 Jun, 2015 | Expired |
| US7214684 | Methods for the treatment of allergic rhinitis | 30 Jun, 2015 | Expired |
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof | 16 Jun, 2015 | Expired |
| US5767082 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists | 16 Jun, 2015 | Expired |
| US5607697 | Taste masking microparticles for oral dosage forms | 07 Jun, 2015 | Expired |
| US5687710 | Inhaler for powdered medications having spiral deagglomeration chamber | 18 May, 2015 | Expired |
| US5686104 | Stable oral CI-981 formulation and process of preparing same | 11 May, 2015 | Expired |
| US7211582 | Methods for treating urticaria using descarboethoxyloratadine | 30 Dec, 2014 | Expired |
| US7214683 | Compositions of descarboethoxyloratadine | 30 Dec, 2014 | Expired |
| US7214684 | Methods for the treatment of allergic rhinitis | 30 Dec, 2014 | Expired |
| US5687710 | Inhaler for powdered medications having spiral deagglomeration chamber | 18 Nov, 2014 | Expired |
| US5686104 | Stable oral CI-981 formulation and process of preparing same | 11 Nov, 2014 | Expired |
| US5889015 | Use of mometasone furoate for treating lower airway passage and lung diseases | 27 Jul, 2014 | Expired |
| US6057307 | Use of mometasone furoate for treating airway passage and lung diseases | 27 Jul, 2014 | Expired |
| US6365581 | Use of mometasone furoate for treating airway passage and lung diseases | 27 Jul, 2014 | Expired |
| US6677322 | Use of mometasone furoate for treating airway passage and lung diseases | 27 Jul, 2014 | Expired |
| US6949532 | Use of mometasone furoate for treating airway passage and lung diseases | 27 Jul, 2014 | Expired |
| US5837699 | Use of mometasone furoate for treating upper airway passage diseases | 27 Jul, 2014 | Expired |
| US6723713 | Use of mometasone furoate for treating upper airway diseases | 27 Jul, 2014 | Expired |
| US5457895 | Method of identifying freeze-dried dosage forms | 01 Apr, 2014 | Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors | 21 Mar, 2014 | Expired |
| US5889015 | Use of mometasone furoate for treating lower airway passage and lung diseases | 27 Jan, 2014 | Expired |
| US6057307 | Use of mometasone furoate for treating airway passage and lung diseases | 27 Jan, 2014 | Expired |
| US6365581 | Use of mometasone furoate for treating airway passage and lung diseases | 27 Jan, 2014 | Expired |
| US6677322 | Use of mometasone furoate for treating airway passage and lung diseases | 27 Jan, 2014 | Expired |
| US6949532 | Use of mometasone furoate for treating airway passage and lung diseases | 27 Jan, 2014 | Expired |
| US6677323 | Use of mometasone furoate for treating airway passage and lung diseases | 27 Jan, 2014 | Expired |
| US5837699 | Use of mometasone furoate for treating upper airway passage diseases | 27 Jan, 2014 | Expired |
| US6723713 | Use of mometasone furoate for treating upper airway diseases | 27 Jan, 2014 | Expired |
| US5571817 | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] | 05 Nov, 2013 | Expired |
| US5547957 | Method of treating androgenic alopecia with 5-α reductase inhibitors | 15 Oct, 2013 | Expired |
| US5457895 | Method of identifying freeze-dried dosage forms | 01 Oct, 2013 | Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors | 21 Sep, 2013 | Expired |
| US5358941 | Dry mix formulation for bisphosphonic acids with lactose | 02 Jun, 2013 | Expired |
| US5681590 | Dry mix formulation for bisphosphonic acids | 02 Jun, 2013 | Expired |
| US6090410 | Dry mix formulation for bisphosphonic acids | 02 Jun, 2013 | Expired |
| US6194004 | Dry mix formulation for bisphosphonic acids | 02 Jun, 2013 | Expired |
| US5418226 | Monoquaternary 2,16-bispiperidinylandrostane derivatives | 14 Apr, 2013 | Expired |
| US5298520 | Triazole containing indole derivatives | 29 Dec, 2012 | Expired |
| US5394868 | Inhalation device for powdered medicaments | 25 Dec, 2012 | Expired |
| US5358941 | Dry mix formulation for bisphosphonic acids with lactose | 02 Dec, 2012 | Expired |
| US5681590 | Dry mix formulation for bisphosphonic acids | 02 Dec, 2012 | Expired |
| US6090410 | Dry mix formulation for bisphosphonic acids | 02 Dec, 2012 | Expired |
| US6194004 | Dry mix formulation for bisphosphonic acids | 02 Dec, 2012 | Expired |
| US5886184 | Finasteride processes | 19 Nov, 2012 | Expired |
| US5565473 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | 03 Aug, 2012 | Expired |
| US5602162 | Imidazole, triazole and tetrazole derivatives | 28 Jul, 2012 | Expired |
Latest Legal Activities on Organon's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Organon.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 01 Jul, 2024 | US8187630 |
| Petition Requesting Trial | 13 May, 2024 | US11590088 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Apr, 2024 | US10821277 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US10195160 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US10195160 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Jan, 2024 | US8187630 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Oct, 2023 | US10647649 |
|
Expire Patent
Critical
| 02 Oct, 2023 | US8007830 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US10195160 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US10195160 |
|
Maintenance Fee Reminder Mailed
Critical
| 19 Apr, 2023 | US8007830 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 11 Apr, 2023 | US11622945 |
|
Recordation of Patent Grant Mailed
Critical
| 11 Apr, 2023 | US11622945 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 04 Apr, 2023 | US11617724 |
|
Recordation of Patent Grant Mailed
Critical
| 04 Apr, 2023 | US11617724 |
Organon's Drug Patent Litigations
Organon's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 09, 2004, against patent number US7214683. The petitioner , challenged the validity of this patent, with ABERG et al as the respondent. Click below to track the latest information on how companies are challenging Organon's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11590088 | April, 2024 | Pending | Dermavant Sciences GmbH et al. | Encube Ethicals Pvt. Ltd. |
| US11590088 | April, 2024 |
Terminated-Adverse Judgment
(07 Mar, 2025)
| Dermavant Sciences GmbH et al. | Encube Ethicals Pvt. Ltd. |
| US7405223 | June, 2007 |
Decision
(21 Feb, 2008)
| Melton B. Affrime et al | |
| US7214683 | December, 2004 |
Decision
(24 Mar, 2005)
| ABERG et al | |
Organon Drug Patents' Oppositions Filed in EPO
Organon drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 22, 2008, by Egis Gyógyszergyár Nyrt. This opposition was filed on patent number EP02707500A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16725243A | Feb, 2023 | SANDOZ AG | Granted and Under Opposition |
| EP18182632A | Jun, 2021 | Consilient Health Limited | Granted and Under Opposition |
| EP06707783A | Apr, 2019 | Holme Patent A/S | Granted and Under Opposition |
| EP06707776A | May, 2017 | ELKINGTON AND FIFE LLP | Opposition rejected |
| EP02770534A | Jul, 2009 | TEVA PHARMACEUTICAL INDUSTRIES LTD. | Opposition procedure closed |
| EP02801836A | Nov, 2008 | Hexal AG | Revoked |
| EP02707500A | Feb, 2008 | EGIS Gyógyszergyár Nyrt | Revoked |
Organon's Family Patents
Organon Drug List
Given below is the complete list of Organon's drugs and the patents protecting them.
1. Asmanex Hfa
Asmanex Hfa is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6068832 | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
27 Aug, 2017
(8 years ago)
| Expired |
| US5889015
(Pediatric)
| Use of mometasone furoate for treating lower airway passage and lung diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US6057307
(Pediatric)
| Use of mometasone furoate for treating airway passage and lung diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US6365581
(Pediatric)
| Use of mometasone furoate for treating airway passage and lung diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US5889015 | Use of mometasone furoate for treating lower airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
| US6057307 | Use of mometasone furoate for treating airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
| US6365581 | Use of mometasone furoate for treating airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Asmanex Hfa's drug page
2. Asmanex Twisthaler
Asmanex Twisthaler is protected by 21 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6503537
(Pediatric)
| Preparation of powder agglomerates |
17 Sep, 2018
(7 years ago)
| Expired |
| US8173172
(Pediatric)
| Preparation of powder agglomerates |
17 Sep, 2018
(7 years ago)
| Expired |
| US6503537 | Preparation of powder agglomerates |
17 Mar, 2018
(7 years ago)
| Expired |
| US8173172 | Preparation of powder agglomerates |
17 Mar, 2018
(7 years ago)
| Expired |
| US6240918
(Pediatric)
| Powdered medication inhaler |
20 Aug, 2017
(8 years ago)
| Expired |
| US6240918 | Powdered medication inhaler |
20 Feb, 2017
(8 years ago)
| Expired |
| US5829434
(Pediatric)
| Inhaler for powdered medications |
03 May, 2016
(9 years ago)
| Expired |
| US5829434 | Inhaler for powdered medications |
03 Nov, 2015
(10 years ago)
| Expired |
| US5687710
(Pediatric)
| Inhaler for powdered medications having spiral deagglomeration chamber |
18 May, 2015
(10 years ago)
| Expired |
| US5687710 | Inhaler for powdered medications having spiral deagglomeration chamber |
18 Nov, 2014
(11 years ago)
| Expired |
| US5889015
(Pediatric)
| Use of mometasone furoate for treating lower airway passage and lung diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US6057307
(Pediatric)
| Use of mometasone furoate for treating airway passage and lung diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US6365581
(Pediatric)
| Use of mometasone furoate for treating airway passage and lung diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US6677322
(Pediatric)
| Use of mometasone furoate for treating airway passage and lung diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US6949532
(Pediatric)
| Use of mometasone furoate for treating airway passage and lung diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US5889015 | Use of mometasone furoate for treating lower airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
| US6057307 | Use of mometasone furoate for treating airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
| US6365581 | Use of mometasone furoate for treating airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
| US6677322 | Use of mometasone furoate for treating airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
| US6949532 | Use of mometasone furoate for treating airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
| US5394868
(Pediatric)
| Inhalation device for powdered medicaments |
25 Dec, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Asmanex Twisthaler's drug page
3. Clarinex
Clarinex is protected by 14 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7618649
(Pediatric)
| Extended release oral dosage composition |
19 Jun, 2021
(4 years ago)
| Expired |
| US7618649 | Extended release oral dosage composition |
19 Dec, 2020
(5 years ago)
| Expired |
| US6100274
(Pediatric)
| 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jan, 2020
(6 years ago)
| Expired |
| US7405223
(Pediatric)
| Treating allergic and inflammatory conditions |
07 Jan, 2020
(6 years ago)
| Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jul, 2019
(6 years ago)
| Expired |
| US7405223 | Treating allergic and inflammatory conditions |
07 Jul, 2019
(6 years ago)
| Expired |
| US5607697
(Pediatric)
| Taste masking microparticles for oral dosage forms |
07 Dec, 2015
(10 years ago)
| Expired |
| US7211582
(Pediatric)
| Methods for treating urticaria using descarboethoxyloratadine |
30 Jun, 2015
(10 years ago)
| Expired |
| US7214683
(Pediatric)
| Compositions of descarboethoxyloratadine |
30 Jun, 2015
(10 years ago)
| Expired |
| US7214684
(Pediatric)
| Methods for the treatment of allergic rhinitis |
30 Jun, 2015
(10 years ago)
| Expired |
| US5607697 | Taste masking microparticles for oral dosage forms |
07 Jun, 2015
(10 years ago)
| Expired |
| US7211582 | Methods for treating urticaria using descarboethoxyloratadine |
30 Dec, 2014
(11 years ago)
| Expired |
| US7214683 | Compositions of descarboethoxyloratadine |
30 Dec, 2014
(11 years ago)
| Expired |
| US7214684 | Methods for the treatment of allergic rhinitis |
30 Dec, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clarinex's drug page
4. Clarinex-d 12 Hour
Clarinex-d 12 Hour is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7618649
(Pediatric)
| Extended release oral dosage composition |
19 Jun, 2021
(4 years ago)
| Expired |
| US6709676 | Extended release oral dosage composition |
18 Feb, 2021
(4 years ago)
| Expired |
| US7618649 | Extended release oral dosage composition |
19 Dec, 2020
(5 years ago)
| Expired |
| US8187630 | Extended release oral dosage composition |
19 Dec, 2020
(5 years ago)
| Expired |
| US6100274
(Pediatric)
| 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jan, 2020
(6 years ago)
| Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jul, 2019
(6 years ago)
| Expired |
| US7214683
(Pediatric)
| Compositions of descarboethoxyloratadine |
30 Jun, 2015
(10 years ago)
| Expired |
| US7214684
(Pediatric)
| Methods for the treatment of allergic rhinitis |
30 Jun, 2015
(10 years ago)
| Expired |
| US7214683 | Compositions of descarboethoxyloratadine |
30 Dec, 2014
(11 years ago)
| Expired |
| US7214684 | Methods for the treatment of allergic rhinitis |
30 Dec, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clarinex-d 12 Hour's drug page
5. Clarinex D 24 Hour
Clarinex D 24 Hour is protected by 11 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7820199
(Pediatric)
| Stable extended release oral dosage composition |
28 Sep, 2022
(3 years ago)
| Expired |
| US6979463 | Stable extended release oral dosage composition |
28 Mar, 2022
(3 years ago)
| Expired |
| US7820199 | Stable extended release oral dosage composition |
28 Mar, 2022
(3 years ago)
| Expired |
| US7618649
(Pediatric)
| Extended release oral dosage composition |
19 Jun, 2021
(4 years ago)
| Expired |
| US7618649 | Extended release oral dosage composition |
19 Dec, 2020
(5 years ago)
| Expired |
| US6100274
(Pediatric)
| 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jan, 2020
(6 years ago)
| Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jul, 2019
(6 years ago)
| Expired |
| US7214683
(Pediatric)
| Compositions of descarboethoxyloratadine |
30 Jun, 2015
(10 years ago)
| Expired |
| US7214684
(Pediatric)
| Methods for the treatment of allergic rhinitis |
30 Jun, 2015
(10 years ago)
| Expired |
| US7214683 | Compositions of descarboethoxyloratadine |
30 Dec, 2014
(11 years ago)
| Expired |
| US7214684 | Methods for the treatment of allergic rhinitis |
30 Dec, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clarinex D 24 Hour's drug page
Explore Our Curated Drug Screens
6. Dulera
Dulera is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7067502
(Pediatric)
| Combinations of formoterol and mometasone furoate for asthma |
21 Nov, 2020
(5 years ago)
| Expired |
| US7566705
(Pediatric)
| Combination of formoterol and mometasone furoate for asthma |
21 Nov, 2020
(5 years ago)
| Expired |
| US7067502 | Combinations of formoterol and mometasone furoate for asthma |
21 May, 2020
(5 years ago)
| Expired |
| US7566705 | Combination of formoterol and mometasone furoate for asthma |
08 May, 2020
(5 years ago)
| Expired |
| US6068832 | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
27 Aug, 2017
(8 years ago)
| Expired |
| US5889015
(Pediatric)
| Use of mometasone furoate for treating lower airway passage and lung diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US6057307
(Pediatric)
| Use of mometasone furoate for treating airway passage and lung diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US5889015 | Use of mometasone furoate for treating lower airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
| US6057307 | Use of mometasone furoate for treating airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
| US6677323 | Use of mometasone furoate for treating airway passage and lung diseases |
27 Jan, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dulera's drug page
7. Follistim
Follistim is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
16 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Follistim's drug page
8. Follistim Aq
Follistim Aq is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7446090 | FSH formulation |
23 Aug, 2019
(6 years ago)
| Expired |
| US7563763 | FSH and FSH variant formulations, products and methods |
23 Aug, 2019
(6 years ago)
| Expired |
| US5929028 | Liquid gonadotropin containing formulations |
14 Jan, 2018
(7 years ago)
| Expired |
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
16 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Follistim Aq's drug page
9. Fosamax
Fosamax is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5358941
(Pediatric)
| Dry mix formulation for bisphosphonic acids with lactose |
02 Jun, 2013
(12 years ago)
| Expired |
| US5681590
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(12 years ago)
| Expired |
| US6090410
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(12 years ago)
| Expired |
| US6194004
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(12 years ago)
| Expired |
| US5358941 | Dry mix formulation for bisphosphonic acids with lactose |
02 Dec, 2012
(13 years ago)
| Expired |
| US5681590 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(13 years ago)
| Expired |
| US6090410 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(13 years ago)
| Expired |
| US6194004 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fosamax's drug page
10. Fosamax Plus D
Fosamax Plus D is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5994329
(Pediatric)
| Method for inhibiting bone resorption |
17 Jan, 2019
(6 years ago)
| Expired |
| US5994329 | Method for inhibiting bone resorption |
17 Jul, 2018
(7 years ago)
| Expired |
| US5358941
(Pediatric)
| Dry mix formulation for bisphosphonic acids with lactose |
02 Jun, 2013
(12 years ago)
| Expired |
| US5681590
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(12 years ago)
| Expired |
| US6090410
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(12 years ago)
| Expired |
| US5358941 | Dry mix formulation for bisphosphonic acids with lactose |
02 Dec, 2012
(13 years ago)
| Expired |
| US5681590 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(13 years ago)
| Expired |
| US6090410 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fosamax Plus D's drug page
11. Ganirelix Acetate
Ganirelix Acetate is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6653286 | Gonadotropin releasing hormone antagonist |
16 Jun, 2018
(7 years ago)
| Expired |
| US5767082 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists |
16 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ganirelix Acetate's drug page
12. Implanon
Implanon is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9757552 | Applicator for inserting an implant |
28 Jul, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Implanon's drug page
13. Liptruzet
Liptruzet is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE42461
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(8 years ago)
| Expired |
| US5969156
(Pediatric)
| Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
08 Jan, 2017
(9 years ago)
| Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(9 years ago)
| Expired |
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
08 Jul, 2016
(9 years ago)
| Expired |
| US5686104
(Pediatric)
| Stable oral CI-981 formulation and process of preparing same |
11 May, 2015
(10 years ago)
| Expired |
| US5686104 | Stable oral CI-981 formulation and process of preparing same |
11 Nov, 2014
(11 years ago)
| Expired |
| US5846966
(Pediatric)
| Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Mar, 2014
(11 years ago)
| Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Sep, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Liptruzet's drug page
14. Maxalt
Maxalt is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5298520
(Pediatric)
| Triazole containing indole derivatives |
29 Dec, 2012
(13 years ago)
| Expired |
| US5602162
(Pediatric)
| Imidazole, triazole and tetrazole derivatives |
28 Jul, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Maxalt's drug page
15. Maxalt-mlt
Maxalt-mlt is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5457895
(Pediatric)
| Method of identifying freeze-dried dosage forms |
01 Apr, 2014
(11 years ago)
| Expired |
| US5457895 | Method of identifying freeze-dried dosage forms |
01 Oct, 2013
(12 years ago)
| Expired |
| US5298520
(Pediatric)
| Triazole containing indole derivatives |
29 Dec, 2012
(13 years ago)
| Expired |
| US5602162
(Pediatric)
| Imidazole, triazole and tetrazole derivatives |
28 Jul, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Maxalt-mlt's drug page
16. Nasonex
Nasonex is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6127353
(Pediatric)
| Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
03 Apr, 2018
(7 years ago)
| Expired |
| US6127353 | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
03 Oct, 2017
(8 years ago)
| Expired |
| US5837699
(Pediatric)
| Use of mometasone furoate for treating upper airway passage diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US6723713
(Pediatric)
| Use of mometasone furoate for treating upper airway diseases |
27 Jul, 2014
(11 years ago)
| Expired |
| US5837699 | Use of mometasone furoate for treating upper airway passage diseases |
27 Jan, 2014
(11 years ago)
| Expired |
| US6723713 | Use of mometasone furoate for treating upper airway diseases |
27 Jan, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nasonex's drug page
17. Nexplanon
Nexplanon is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9757552 | Applicator for inserting an implant |
28 Jul, 2030
(4 years from now)
| Active |
| US8722037 | X-ray visible drug delivery device |
28 Sep, 2027
(1 year, 8 months from now)
| Active |
| US10821277 | Kit for and method of assembling an applicator for inserting an implant |
31 May, 2027
(1 year, 4 months from now)
| Active |
| US8888745 | Applicator for inserting an implant |
28 Aug, 2026
(7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexplanon's drug page
18. Nuvaring
Nuvaring is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5989581 | Drug delivery system for two or more active substances |
08 Apr, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nuvaring's drug page
19. Propecia
Propecia is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5571817 | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] |
05 Nov, 2013
(12 years ago)
| Expired |
| US5547957 | Method of treating androgenic alopecia with 5-α reductase inhibitors |
15 Oct, 2013
(12 years ago)
| Expired |
| US5886184 | Finasteride processes |
19 Nov, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Propecia's drug page
20. Proscar
Proscar is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5942519 | Prevention of precipitated acute urinary retention |
23 Oct, 2018
(7 years ago)
| Expired |
| US5886184 | Finasteride processes |
19 Nov, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Proscar's drug page
21. Raplon
Raplon is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5418226 | Monoquaternary 2,16-bispiperidinylandrostane derivatives |
14 Apr, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Raplon's drug page
22. Singulair
Singulair is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8007830 | Granule formation |
24 Oct, 2022
(3 years ago)
| Expired |
| US5565473
(Pediatric)
| Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
03 Aug, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Singulair's drug page
23. Vtama
Vtama is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11497718 | Use of tapinarof for the treatment of atopic dermatitis |
13 Nov, 2039
(13 years from now)
| Active |
| US11590088 | Use of Tapinarof for the treatment of chronic plaque psoriasis |
13 Nov, 2039
(13 years from now)
| Active |
| US11938099 | Use of tapinarof for the treatment of atopic dermatitis |
13 Nov, 2039
(13 years from now)
| Active |
| US10647649 | Process for preparing tapinarof |
13 Nov, 2038
(12 years from now)
| Active |
| US11597692 | Process for preparing tapinarof |
13 Nov, 2038
(12 years from now)
| Active |
| US10195160 | Topical pharmaceutical compositions |
19 May, 2036
(10 years from now)
| Active |
| US10426743 | Topical pharmaceutical compositions |
19 May, 2036
(10 years from now)
| Active |
| US11458108 | Topical pharmaceutical compositions |
19 May, 2036
(10 years from now)
| Active |
| US11612573 | Topical pharmaceutical compositions |
19 May, 2036
(10 years from now)
| Active |
| US11617724 | Topical pharmaceutical compositions |
19 May, 2036
(10 years from now)
| Active |
| US11622945 | Topical pharmaceutical compositions |
19 May, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vtama's drug page
24. Vytorin
Vytorin is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE37721
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(8 years ago)
| Expired |
| USRE42461
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(8 years ago)
| Expired |
| USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(9 years ago)
| Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(9 years ago)
| Expired |
| US5846966
(Pediatric)
| Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Mar, 2014
(11 years ago)
| Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Sep, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vytorin's drug page
25. Xaciato
Xaciato is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11129896 | Topical formulations and treatments |
22 Sep, 2036
(10 years from now)
| Active |
| US12303563 | Topical formulations and treatments |
22 Sep, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xaciato's drug page
26. Zetia
Zetia is protected by 10 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7612058
(Pediatric)
| Methods for inhibiting sterol absorption |
30 Apr, 2026
(3 months from now)
| Active |
| US7612058 | Methods for inhibiting sterol absorption |
30 Oct, 2025
(2 months ago)
| Expired |
| US7030106
(Pediatric)
| Sterol absorption inhibitor compositions |
25 Jul, 2022
(3 years ago)
| Expired |
| US7030106 | Sterol absorption inhibitor compositions |
25 Jan, 2022
(3 years ago)
| Expired |
| USRE37721
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(8 years ago)
| Expired |
| USRE42461
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(8 years ago)
| Expired |
| USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(9 years ago)
| Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(9 years ago)
| Expired |
| US5846966
(Pediatric)
| Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Mar, 2014
(11 years ago)
| Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Sep, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zetia's drug page